{"id":"NCT03630705","sponsor":"Sanofi Pasteur, a Sanofi Company","briefTitle":"Safety and Immunogenicity of a Quadrivalent Meningococcal Conjugate Vaccine When Administered Concomitantly With Routine Pediatric Vaccines in Healthy Infants and Toddlers in the Russian Federation and Mexico","officialTitle":"Safety and Immunogenicity of a 3-Dose Schedule of an Investigational Quadrivalent Meningococcal Conjugate Vaccine When Administered Concomitantly With Routine Pediatric Vaccines in Healthy Infants and Toddlers","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2018-10-17","primaryCompletion":"2022-02-18","completion":"2022-02-18","firstPosted":"2018-08-15","resultsPosted":"2023-10-19","lastUpdate":"2023-10-19"},"enrollment":525,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"PREVENTION"},"conditions":["Healthy Volunteers (Meningococcal Infection)"],"interventions":[{"type":"BIOLOGICAL","name":"Meningococcal Polysaccharide (Serogroups A, C, Y, and W) Tetanus Toxoid Conjugate Vaccine","otherNames":[]},{"type":"BIOLOGICAL","name":"Meningococcal (Groups A, C, Y and W 135) Oligosaccharide Diphtheria CRM197 Conjugate Vaccine","otherNames":["Menveo®"]},{"type":"BIOLOGICAL","name":"Measles, Mumps, and Rubella Virus Vaccine Live","otherNames":["M-M-R®II"]},{"type":"BIOLOGICAL","name":"Pneumococcal 13-valent Conjugate Vaccine","otherNames":["Prevnar 13®"]},{"type":"BIOLOGICAL","name":"Diphtheria, Tetanus, Pertussis (Acellular, Component) Poliomyelitis (inactivated) Vaccine, and Haemophilus influenza type b Conjugate Vaccine","otherNames":["Pentaxim®"]},{"type":"BIOLOGICAL","name":"Hepatitis B Vaccine","otherNames":["ENGERIX-B®"]},{"type":"BIOLOGICAL","name":"Rotavirus Vaccine, Live, Pentavalent","otherNames":["RotaTeq®"]},{"type":"BIOLOGICAL","name":"Diphtheria, tetanus, pertussis (acellular component), hepatitis B, poliomyelitis (inactivated), and Haemophilus influenzae type b conjugate vaccine","otherNames":["Hexacima®"]}],"arms":[{"label":"Group 1: MenACYW Conjugate Vaccine (Mexico)","type":"EXPERIMENTAL"},{"label":"Group 2: Menveo® (Mexico)","type":"ACTIVE_COMPARATOR"},{"label":"Group 3: MenACYW Conjugate Vaccine (Russian Federation)","type":"EXPERIMENTAL"},{"label":"Group 4: Routine Pediatric Vaccines (Russian Federation)","type":"OTHER"}],"summary":"Primary Objective:\n\n1. To describe the vaccine seroprotection (antibody titer greater than or equal to \\[\\>=\\] 1:8) to the antigens (meningococcal serogroups A, C, Y, and W) present in MenACYW Conjugate vaccine or Menveo® measured by serum bactericidal assay using human complement (hSBA), for Groups 1 and 2 when administered concomitantly with routine pediatric vaccines in healthy infants and toddlers in Mexico.\n2. To describe the vaccine seroprotection (antibody titer \\>=1:8) to the antigens (meningococcal serogroups A, C, Y, and W) present in MenACYW Conjugate vaccine measured by hSBA, for Group 3, when administered concomitantly with routine pediatric vaccines in healthy infants and toddlers in the Russian Federation.\n\nSecondary Objective:\n\n1. To describe hSBA vaccine seroresponse to the antigens (meningococcal serogroups A, C, Y, and W) 30 days after the last vaccination of the infant series, when administered concomitantly with routine pediatric vaccines in healthy infants and toddlers in Mexico and Russian Federation (RF).\n2. To describe immunogenicity profile of routine pediatric vaccines when administered concomitantly with MenACYW Conjugate vaccine or Menveo®; or when administered alone.\n3. To describe hSBA antibody responses against meningococcal serogroups A, C, Y, and W when MenACYW Conjugate vaccine and Menveo® are administered concomitantly with routine pediatric vaccines in Mexico and RF.\n4. To describe antibody titers to the antigens present in MenACYW Conjugate vaccine and Menveo®, before the first vaccination and 30 days after the last vaccination of the infant series and in the second year of life, when administered concomitantly with routine pediatric vaccines in a subset of participants in Mexico and RF.","primaryOutcome":{"measure":"Percentage of Participants With Antibody Titers Greater Than or Equal to (>=) 1:8 Against Meningococcal Serogroups A, C, Y, and W Following Last Vaccination With MenACYW Conjugate or Menveo® Vaccine: Groups 1 and 2","timeFrame":"30 days after the last vaccination at the age of 12 months (i.e., at the age of 13 months)","effectByArm":[{"arm":"Group 1: MenACYW Conjugate Vaccine (Mexico)","deltaMin":97.6,"sd":null},{"arm":"Group 2: Menveo® Vaccine (Mexico)","deltaMin":95,"sd":null}],"pValues":[]},"eligibility":{"minAge":"2 Months","sex":"ALL","healthyVolunteers":true,"inclusionCount":6,"exclusionCount":24},"locations":{"siteCount":11,"countries":["Mexico","Russia"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":4,"n":201},"commonTop":["Irritability","Injection Site Pain","Crying","Injection Site Erythema","Somnolence"]}}